Benign prostatic hyperplasia progression and its impact on treatment

Current Opinion in Urology

Volumn 14, Issue 1, 2004, Pages 45-50

  Djavan, Bob ^a   Waldert, Matthias ^a   Ghawidel, Clemens ^a   Marberger, Michael ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Benign prostatic hyperplasia progression; Prostatic specific antigen; Risk factors; Survey; Symptoms; Urodynamics

Indexed keywords

DOXAZOSIN; DUTASTERIDE; FINASTERIDE; STEROID 5ALPHA REDUCTASE INHIBITOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT;

ATTITUDE; CANCER GROWTH; CANCER RISK; CLINICAL TRIAL; DISEASE MARKER; HUMAN; LONG TERM CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; RISK REDUCTION; URINE RETENTION; AGED; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; FOLLOW UP; HOSPITALIZATION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; TREATMENT OUTCOME; URODYNAMICS;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; DISEASE PROGRESSION; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; URINARY RETENTION; URODYNAMICS;

EID: 2342633763     PISSN: 09630643     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042307-200401000-00010     Document Type: Review

References (42)

1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132:474-479.
2. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol 1993; 150:85-89.
3. Ball A, Feneley RC, Abrams PH. The natural history of untreated 'prostatism'. J Urol 1981; 53:613-616.
4. Barry MJ, Fowler FJ Jr, Bin L, et al. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997; 157:10-14.
5. Jacobsen SJ, Jacobsen DJ, Girman CJ, et al. Natural history of prostatism: risk factors for acute urinary retention. J Urol 1997; 158:481-487.
6. Roberts RO, Jacobsen SJ, Jacobson DJ, et al. Longitudinal changes in peak urinary flow rates in a community-based cohort. J Urol 2000; 163:107-113.
7. Roehrborn CG, McConnell JD, Lieber M, et al. Serum prostate-specific antigen is a powerful predictor of acute urinary retention and the need for surgery in men with clinical benign prostatic hyperplasia. Urology 1999; 53:473-480.
8. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. Urology 1999; 54:662-669.
9. Marberger MJ, Andersen JT, Nickel JC, et al. Prostate volume and serum prostate-specific antigen as predictors of acute urinary retention. Eur Urol 2000; 38:563-568.
10. Jacobsen SJ, Girman CJ, Guess HA, et al. Natural history of prostatism: longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996; 155:595-600.
11. Lee AJ, Russell AW, Garraway WM, Prescott RJ. Three-year follow up of a community based cohort of men with untreated benign prostatic hyperplasia. Eur Urol 1996; 30:11-17.
12. Bruskewitz R, Girman CJ, Fowler J, et al. Effect of finasteride on bother and other health related quality of life aspects associated with benign prostatic hyperplasia. Urology 1999; 54:670-678.
13. Flanigan RC, Reda DJ, Wasson JH, et al. 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 1998; 160:12-17.
14. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002; 60:434-441.
15. Meigs JB, Barry MJ, Giovannucci E, Kawachi I. Incidence rates and risk factors for acute urinary retention: the health professionals follow up study. J Urol 1999; 162:376-382.
16. Girman CJ, Jacobsen SJ, Tsukamoto T, et al. Health-related quality of life associated with lower urinary tract symptoms in four countries. Urology 1998; 51:428-436.
17. Girman CJ, Epstein RS, Jacobsen SJ, et al. Natural history of prostatism: impact of urinary symptoms on quality of life in 2115 randomly selected community men. Urology 1994; 44:825-831.
18. Girman CJ, Jacobsen SJ, Rhodes T, et al. Association of health-related quality of life and benign prostatic enlargement. Eur Urol 1999; 35:277-284.
19. Roberts RO, Jacobsen SJ, Rhodes T, et al. Natural history of prostatism: impaired health states in men with lower urinary tract symptoms. J Urol 1997; 157:1711-1717.
20. Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognized benign prostatic hyperplasia on the daily activities of middle-aged and elderly men. Br J Gen Pract 1993; 43:318-321.
21. Tsang KK, Garraway WM. Impact of benign prostatic hyperplasia on general well-being of men. Prostate 1993; 23:1-7.
22. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999; 6:819-822.
23. Sells H, Donovan J, Ewings P, MacDonagh RP. The development and validation of a quality-of-life measure to assess partner morbidity in benign prostatic enlargement. BJU Int 2000; 85:440-445.
24. Djavan B, Nickel JC, de la Rosette J, Abrams P. The urologist view of BPH progression: results of an international survey. Eur Urol 2002; 41:490-496.
25. Roehrborn CG, Boyle P, Gould AL, Waldstreicher J. Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia. Urology 1999; 53:581-589.
26. Roehrborn CG, Malice PP, Cook TK, Girman CJ. Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials. Urology 2001; 58:210-216.
27. Wright EJ, Fang J, Metter EJ, et al. Prostate specific antigen predicts the long-term risk of prostate enlargement: results from the Baltimore Longitudinal Study of Aging. J Urol 2002; 167:2484-2487; discussion 2487-2488.
28. Hochberg DA, Armenkas NA, Fracchia JA. Relationship of prostate-specific antigen and prostate volume in patients with biopsy proven benign prostatic hyperplasia. Prostate 2000; 45:315-319.
29. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2001; 39:390-399.
30. Roehrborn CG, Boyle P, Bergner D, et al. Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology 1999; 54:662-669.
31. Arrighi HM, Guess HA, Metter EJ, Fozard JL. Symptoms and signs of prostatism as risk factors for prostatectomy. Prostate 1990; 16:253-261.
32. Roehrborn CG, Girman CJ, Rhodes T, et al. Correlation between prostate size estimated by digital rectal examination and measured by transrectal ultrasound. Urology 1997; 49:548-557.
33. Roehrborn CG. Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. Urology 1998; 51 (4A Suppl):19-22.
34. Roehrborn CG, McConnell JD, Bonilla J, et al. Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study. J Urol 2000; 163:13-20.
35. Djavan B, Wammack R, Dobrovits M, et al. Predictors of progression in men with mild symptoms of bladder outlet obstruction. J Urol 2002; 167 (Suppl.):268.
36. Boyle P, Robertson C, Wilson T, Benichou J. Risk factors for acute urinary retention in men with benign prostatic hyperplasia. Abstract presented at the XVIIIth European Association of Urology Annual Congress; Madrid, Spain; 2003.
37. The impact of medical therapy on the clinical progression of BPH: results of the MTOPS trial. The MTOPS Research Group. Abstract presented at the American Urological Association Annual Meeting; Atlanta 2002. J Urol 2002; 167 (Suppl):265.
38. McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of AUR and the need for surgical treatment among men with benign prostatic hyperplasia. New Engl J Med 1998; 338:557-563.
39. Barry MJ. The BPH Impact Index. In: Cockett ATK, Khoury S, Aso Y, et al., editors. Proceedings of the 3rd International Consultation on BPH; 26-28 June 1996; Monaco. Scientific Communication International Ltd; Jersey, Channel Islands 1996. pp. 275-276.
40. Barry MJ, Batista JE, Donovan J, et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo KT, et al., editors. The 5th International Consultation on Benign Prostatic Hyperplasia (BPH); 25-28 June 2000; Paris. Health Publication Limited; Jersey, Channel Islands 2000. pp. 221-225.
41. Garraway WM, Russell EB, Lee RJ, et al. Impact of previously unrecognised benign prostatic hyperplasia on the daily living activities of middle-aged and elderly men. Br J Gen Pract 1993; 43:318-321.
42. Kawakami J, Nickel JC. Acute urinary retention and surgery for benign prostatic hyperplasia: the patient's perspective. Can J Urol 1999; 6:819-822.